9 Meters Biopharma Announces Management Change And Provides Clinical Update On Vurolenatide In Patients With Short Bowel Syndrome; John Temperato Resigns As President And Chief Executive Officer Of The Company Effective Immediately
Portfolio Pulse from Happy Mohamed
9 Meters Biopharma announces the resignation of John Temperato as President and CEO, with CFO Bethany Sensenig appointed as interim CEO. The company is considering an additional Phase 2 trial for vurolenatide in patients with short bowel syndrome, following feedback from the FDA and other stakeholders.
May 30, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
9 Meters Biopharma's CEO John Temperato resigns, and the company is considering an additional Phase 2 trial for vurolenatide in short bowel syndrome patients.
The resignation of the CEO may cause short-term uncertainty for the company, but the appointment of an interim CEO should help maintain stability. The consideration of an additional Phase 2 trial for vurolenatide may delay the drug's development, but it could also maximize its potential, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100